SCHEMBL17397997

SCHEMBL17397997

Clc1cc(SCc2ccccc2)cc(Cl)n1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAOA P21397 3/20 0.46
MAOB P27338 3/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP3A4 P08684 1/20 0.45
SCN9A Q15858 1/20 0.44
DAO P14920 1/20 0.41
ALOX15 P16050 1/20 0.41
SLC6A4 P31645 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL489903 0.81 RAB9A (0.62) L3MBTL1RAB9ANPC1SMN1; SMN2HSD17B10
SCHEMBL9876887 0.80 HSD17B10 (0.50) RAB9ANPC1SMN1; SMN2MAOAMAOB
SCHEMBL7104561 0.80 MAOA (0.49) POLBL3MBTL1RAB9ANPC1SMN1; SMN2
SCHEMBL16296844 0.79 SCN9A (0.50) POLBCTDSP1L3MBTL1RAB9ANPC1
SCHEMBL21464176 0.78 HTT (0.52) POLBL3MBTL1SMN1; SMN2CYP3A4LMNA
SCHEMBL30826790 0.78 HTT (0.52) POLBL3MBTL1SMN1; SMN2CYP3A4LMNA
SCHEMBL31647232 0.78 APP (0.55) L3MBTL1RAB9ANPC1SMN1; SMN2MAOA
SCHEMBL22553421 0.77 KMT2A (0.48) POLBCTDSP1L3MBTL1RAB9ANPC1
SCHEMBL31468118 0.76 CYP3A4 (0.49) POLBCTDSP1L3MBTL1RAB9ANPC1
SCHEMBL22865221 0.76 MAOA (0.45) POLBL3MBTL1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417387-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2024-12-19 US disclosed
EP-4416140-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2024-08-21 EP disclosed
CN-118076594-A Sulfonylpiperazinyl compounds for the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-05-24 CN disclosed
WO-2023061617-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-20 WO disclosed
WO-2023061617-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-20 WO disclosed
WO-2016001341-A1 SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2016-01-07 WO disclosed
WO-2016001341-A1 SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417387-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS CFTR, KCNQ1, Q6ZSR9 POLB 3512/4885CTDSP1 3644/4885L3MBTL1 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.